Medizinische Universität Graz - Research portal
Selected Publication:
Becker, JC; Pancook, JD; Gillies, SD; Furukawa, K; Reisfeld, RA.
T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy
J EXP MED. 1996; 183(5): 2361-2366.
Doi: 10.1084/jem.183.5.2361
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Becker Jürgen Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Induction of a T-cell mediated antitumor response is the ultimate goal for tumor immunotherapy. We demonstrate here that antibody-targeted IL2 therapy is effective against established pulmonary and hepatic melanoma metastases in a syngeneic murine tumor model. The effector mechanisms involved in this tumor eradication are not dependent on NK cells, since the therapeutic effect of antibody-IL2 fusion protein was not altered in NK cell-deficient mice. In contrast, T cells are essential for the observed antitumor effect, since therapy with antibody-IL2 fusion proteins is unable to induce tumor eradication in T cell-deficient SCID mice. In vivo depletion studies characterized the essential effector cell population further as CD8+ T cells. Such CD8+ T cells, isolated from tumor bearing mice after antibody-directed IL2 therapy, exerted a MHC class I-restricted cytotoxicity against the same tumor in vitro. These data demonstrate the ability of antibody-targeted IL2 delivery to induce a T cell-dependent host immune response that is capable of eradicating established melanoma metastases in clinically relevant organs.